Abstract
Abstract Lupus nephritis (LN) is histologically evident yet early diagnosis can be challenging since some patients do not exhibit overt clinical manifestations until advanced stages. The objective of the present study is to determine if B-cell expression of interferon beta (IFNβ) can be a unique systemic lupus erythematosus (SLE) clinical prognostic marker and if specific histopathologic features of LN can be identified in patients with elevated B-cell expression of IFNβ. A total of 80 patients who met the ACR/EULAR classification criteria of SLE were recruited. LN was identified in 41% (N=33). Multivariate regression analysis indicated a significant positive correlation between naïve B-cell IFNβ with race (African American > European American; P=0.006) and LN class (P<0.0001). Patients with elevated serum anti-Smith (P=0.01) and anti-DNA (P=0.013) exhibited significantly higher naïve B-cell IFNβ. B-cell IFNβ was further compared with renal histopathology microscopy findings on light, electron microscopy, and immunofluorescence (IF) (N=23). Patients with a higher percentage of IFNβ in naïve B cells showed increased segmental scaring (P=0.046). These patients also exhibited aggressive LN class (P=0.14), membranous pattern (P=0.15), and global sclerosis (P=0.18), although the differences were not significant. B-cell IFNβ did not show significant correlation with IgG, IgM, IgA, and C1q, and C3 in situ staining. The present study suggests that B-cell endogenous IFNβ may be developed into a unique target-based marker for the development and severity of LN. IFNβ blockade may be developed into an individualized therapy for this subset of SLE patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call